



**Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class store-operated calcium entry (SOCE) inhibitor in preclinical models of Acute Myeloid Leukemia (AML) at the 2019 AACR-NCI-EORTC Conference in Boston**

La Chaux-de-Fonds, Switzerland, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class SOCE inhibitor in preclinical models of Acute Myeloid Leukemia (AML).

**Highlights from the poster include:**

- *RP4010 demonstrated single-agent activity and remarkable potentiation in activity of standard of care/approved drugs for treating AML*
- *RP4010 potentiated the activity of gilteritinib (XOSPATA®) in reducing cell growth, induction of apoptosis, cell cycle arrest, regulation of expression of genes involved in myeloid differentiation and modulation of downstream markers*
- *RP4010 when combined with cytarabine (ARA-C), demonstrated significant anti-tumor activity in an MV-4-11 xenograft model*

**About RP4010:**

RP4010 is a novel first-in-class oral small molecule inhibitor of store-operated calcium entry (SOCE) with demonstrated preclinical activity in a broad range of cancers. Blockade of SOCE through calcium release-activated calcium (CRAC) channel inhibition could suppress tumor growth via a number of downstream events including inhibition of NFAT dephosphorylation as well as calcium-dependent activation of Akt/NF- $\kappa$ B and ERK 1/2 pathways. A multi-center Phase I/IB dose-escalation trial evaluating the safety and efficacy of RP4010 in patients with relapsed or refractory Lymphomas is currently ongoing in USA and Australia (ClinicalTrials.gov Identifier: NCT03119467).

**Details of the poster presentation:**

**-- Poster Title: RP4010, a small molecule inhibitor of Store-Operated Calcium Entry (SOCE), potentiates activity of Gilteritinib and Cytarabine in preclinical models of AML**

- Session Title: Therapeutic Agents: Other
- Session Date: Tuesday, October 29, 2019
- Session Start Time: 12:30
- Session End Time: 16:00

- Location: Hall D, Hynes Convention Center
- Permanent Abstract No.: C045

**About Rhizen Pharmaceuticals S.A.:**

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen's website, [www.rhizen.com](http://www.rhizen.com).

**Contact:**

Kumar V. Penmetsa, Ph.D.  
Executive Vice President, Corporate Development  
Rhizen Pharmaceuticals S.A.  
Telephone: +1-267-207-5707  
Email: [kvp@rhizen.com](mailto:kvp@rhizen.com)